Annual Report Searches
Alphabetical Search
SYMBOL SEARCH RESULTS: HMC
Total Results: 1
We Do Not Ship To Addresses Outside North America
HONDA MOTOR CO LTD (HMC:NYSE)

Advertisement
ALEXION PHARMACEUTICALS INC (ALXN:NASDAQ)
Alexion is a biopharmaceutical company focused on serving patients with severe and rare disorders through the innovation, development and commercialization of life-transforming therapeutic products. Alexion is the global leader in complement inhibition and has developed and markets Soliris® (eculizumab) as a treatment for patients with PNH and aHUS, two debilitating, ultra-rare and life-threatening disorders caused by chronic uncontrolled complement activation. Soliris is currently approved in nearly 50 countries for the treatment of PNH, and in nearly 40 countries for the treatment of aHUS. Alexion is evaluating other potential indications for Soliris in additional severe and ultra-rare disorders beyond PNH and aHUS, and is developing other highly innovative biotechnology product candidates across multiple therapeutic areas.

Yearly Figures

(in thousands, except per share amounts)
FYE: 12/31 2013 2012 2011 2010
Net Revenues $1,551,346 $1,134,114 $783,431 $540,957
Net Income $252,895 $254,822 $175,315 $97,030
Earnings Per Share 1.27 1.28 0.91 0.52

Quarterly Figures

(in thousands, except per share amounts)
              Third Quarter
FYE: 12/31 9/30/14 9/30/13
Net Revenues $555,146 $400,405
Net Income $177,731 $93,785
Earnings Per Share 0.88 0.47

Contact Information

Contact Name: ADLER IRVING
Contact Title: CORPORATE COMMUNICATIONS
Phone: 1-203-272-2596

Company Information Yearly Figures Quarterly Figures Contact Information Add To Cart Print